RxDoctor Payments Data

Fadi Jaafar

Podiatrist · Alma, MINPI 1679837504

Payments from drug & device makers

What this record shows

This record is dominated by other: $187,800 of the $191,483 with a category attached, or 98.1%. Skye Orthobiologics LLC accounts for 98.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $187,999 and has fallen 100.0% since, to $37 in 2025. Among podiatrist clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$191,483in general payments, 2019–2025

Across 99 payments — averaging $1934.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Skye Orthobiologics LLC$188K
  • Medwest Associates$2K
  • Arthrex$428
  • Stryker$369
  • Amgen$262
  • Organogenesis Inc.$200
  • plus $772 from 14 others

What the payments were for

  • Travel & lodging$1,2251%
  • Food & beverage$1,7131%
  • Education$7460%
  • Other$187,80098%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$191,483 in reported general payments places this provider in the 95th percentile of 302 podiatrist providers in Michigan.

See all podiatrist providers in Michigan

Medicare billing

Part B allowed, 2024
$549,791
Medicare patients
868
Services billed
3,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ammonium Lactate33$553
Cephalexin19$455
Gabapentin15$140

Paid to pharmacies, not to this prescriber.

Other podiatrist in Alma

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →